Medexus Pharmaceuticals (MDP) Competitors C$2.84 +0.06 (+2.16%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock MDP vs. ICC, CPH, RIV, LEAF, CRDL, RX, HLS, SUGR, TGOD, and NINEShould you be buying Medexus Pharmaceuticals stock or one of its competitors? The main competitors of Medexus Pharmaceuticals include ICC Labs (ICC), Cipher Pharmaceuticals (CPH), RIV Capital (RIV), Leaf Mobile (LEAF), Cardiol Therapeutics (CRDL), BioSyent (RX), HLS Therapeutics (HLS), SugarBud Craft Growers (SUGR), Green Organic Dutchman (TGOD), and Delta 9 Cannabis (NINE). These companies are all part of the "drug manufacturers - specialty & generic" industry. Medexus Pharmaceuticals vs. Its Competitors ICC Labs Cipher Pharmaceuticals RIV Capital Leaf Mobile Cardiol Therapeutics BioSyent HLS Therapeutics SugarBud Craft Growers Green Organic Dutchman Delta 9 Cannabis ICC Labs (CVE:ICC) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation. Which has stronger earnings and valuation, ICC or MDP? Medexus Pharmaceuticals has higher revenue and earnings than ICC Labs. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioICC LabsC$533.68K419.04C$2.35MC$0.0295.29Medexus PharmaceuticalsC$100.25M0.63C$3.26MC$0.2113.58 Is ICC or MDP more profitable? Medexus Pharmaceuticals has a net margin of 3.25% compared to ICC Labs' net margin of 0.00%. Medexus Pharmaceuticals' return on equity of 11.07% beat ICC Labs' return on equity.Company Net Margins Return on Equity Return on Assets ICC LabsN/A N/A N/A Medexus Pharmaceuticals 3.25%11.07%4.89% Do insiders & institutionals believe in ICC or MDP? 8.3% of Medexus Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to ICC or MDP? In the previous week, Medexus Pharmaceuticals had 1 more articles in the media than ICC Labs. MarketBeat recorded 1 mentions for Medexus Pharmaceuticals and 0 mentions for ICC Labs. ICC Labs' average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score. Company Overall Sentiment ICC Labs Neutral Medexus Pharmaceuticals Neutral Do analysts recommend ICC or MDP? Medexus Pharmaceuticals has a consensus price target of C$5.49, indicating a potential upside of 93.22%. Given Medexus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Medexus Pharmaceuticals is more favorable than ICC Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ICC Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Medexus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 4 Strong Buy rating(s) 3.29 SummaryMedexus Pharmaceuticals beats ICC Labs on 13 of the 15 factors compared between the two stocks. Get Medexus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDP vs. The Competition Export to ExcelMetricMedexus PharmaceuticalsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$63.58MC$2.19BC$5.70BC$6.31BDividend YieldN/A2.92%4.69%6.72%P/E Ratio13.584.1928.0775.38Price / Sales0.63587.23448.571,359.95Price / CashN/A10.3536.2283.29Price / Book2.1011.028.664.89Net IncomeC$3.26MC$21.15BC$3.25BC$301.20M7 Day Performance1.07%1.40%4.20%1.18%1 Month Performance-15.22%6.47%10.82%5.58%1 Year Performance33.33%3.07%34.70%26.97% Medexus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDPMedexus Pharmaceuticals1.5389 of 5 starsC$2.84+2.2%C$5.49+93.2%+29.3%C$63.58MC$100.25M13.5898Gap UpICCICC LabsN/AC$1.62-5.8%N/A+0.0%C$223.64MC$533.68K95.29N/AGap UpCPHCipher Pharmaceuticals1.3671 of 5 starsC$12.35-0.6%C$14.75+19.4%+40.6%C$221.72MC$19.03M13.645News CoverageRIVRIV CapitalN/AN/AN/AN/AC$213.65MC$11.33M-1.6312LEAFLeaf MobileN/AN/AN/AN/AC$198.42MC$83.74M58.86150CRDLCardiol TherapeuticsN/AC$1.88+12.6%N/A-36.8%C$156MN/A-3.6920High Trading VolumeRXBioSyentN/AC$11.40-0.4%N/A+13.3%C$130.39MC$34.06M18.50N/ANews CoverageGap UpHLSHLS TherapeuticsN/AC$4.91-1.6%C$4.50-8.4%+52.5%C$109.24MC$40.13M-4.9291SUGRSugarBud Craft GrowersN/AC$13.40-0.7%N/A+62.4%C$91.39MC$575.64M16.1444High Trading VolumeTGODGreen Organic DutchmanN/AN/AN/AN/AC$89.95MC$31.37M-0.6541Gap UpHigh Trading VolumeNINEDelta 9 CannabisN/AC$1.03+3.0%N/A+0.0%C$89.36MC$12.87M19.07940Gap Up Related Companies and Tools Related Companies ICC Labs Competitors Cipher Pharmaceuticals Competitors RIV Capital Competitors Leaf Mobile Competitors Cardiol Therapeutics Competitors BioSyent Competitors HLS Therapeutics Competitors SugarBud Craft Growers Competitors Green Organic Dutchman Competitors Delta 9 Cannabis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:MDP) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDP Stock Alerts